Omicron: Is The End Or A New Beginning?
Özet
The Omicron variant (B.1.529), first detected in South Africa in November 2021, was rapidly designated a variant of concern by the WHO due to a steep rise in infections. Harboring 32 mutations in its spike protein compared to only 5 or 8 in the Delta variant, Omicron exhibits significant evolutionary advantages. These genetic alterations lead to enhanced infectivity, a rapid doubling time, and heightened transmissibility across populations. Furthermore, Omicron demonstrates substantial immune evasion, causing increased rates of reinfection and vaccine breakthrough infections while displaying high resistance against several established monoclonal antibody treatments like bamlanivimab, etesevimab, and imdevimab. Despite these challenging characteristics, experimental and clinical data indicate that Omicron primarily replicates in the human upper respiratory tract and has a significantly reduced impact on the lower respiratory tract and lung tissue compared to previous strains. Consequently, the variant is associated with much milder disease severity, leading to a substantial reduction in hospitalizations, shorter hospital stays, fewer intensive care unit (ICU) admissions, and lower mortality rates. Nevertheless, its unprecedentedly rapid spread continues to pose a major challenge, heavily burdening healthcare systems and emphasizing the ongoing need for booster doses, updated vaccines, and non-pharmacological precautions.
Referanslar
(WHO) 2021. Classification of Omicron. https://www.who.int/news/item/26-11-2021-classification-of-omicron-(b.1.1.529)-sars-cov-2-variant-of-concern (Access Date: 29/01/2022).
Musa SS, Gyeltshen D, Manirambona E, et al. The new COVID-19 omicron variant: Africa must watch its spread! Clin Epidemiol Glob Health. 2022 Jan-Feb;13:100961. doi: 10.1016/j.cegh.2022.100961. Epub 2022 Jan 13.
Kumar S, Thambiraja TS, Karuppanan K, et al. Omicron and Delta variant of SARS-CoV-2: A comparative computational study of spike protein. J Med Virol. 2021 Dec 15. doi: 10.1002/jmv.27526. Epub ahead of print.
The Lancet Infectious Diseases. Emerging SARS-CoV-2 variants: shooting the messenger. Lancet Infect Dis. 2022 Jan;22(1):1. doi: 10.1016/S1473-3099(21)00770-2. Epub 2021 Dec 9.
(Our World in Data) 2021. The COVID-19 Data Explorer. https://ourworldindata.org/search?q=coronavirus+data (Access Date: 30/01/2022).
Kannan S, Shaik Syed Ali P, et al. Omicron (B.1.1.529) - variant of concern - molecular profile and epidemiology: a mini review. Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8019-8022.
(Omicron). 2021. Omicron. https://www.cdc.gov/media/releases/2021/s1126-B11-529-omicron.html (Access Date: 29/01/2022)
(Covid Data Tracker) 2021. https://covid.cdc.gov/covid-data-tracker/#variant-proportions (Access Date: 30/01/2022).
Callaway E. Heavily mutated Omicron variantputs scientists on alert. Nature.2021;600(7887):21. doi:10.1038/d41586-021-03552-w
Nealon J, Cowling BJ. Omicron severity: milder but not mild. Lancet. 2022 Jan 19;399(10323):412–3. doi: 10.1016/S0140-6736(22)00056-3. Epub ahead of print.
Ingraham NE, Ingbar DH. The omicron variant of SARS-CoV-2: Understanding the known and living with unknowns. Clin Transl Med. 2021 Dec;11(12):e685. doi: 10.1002/ctm2.685.
Meo SA, Meo AS, Al-Jassir FF, et al. Omicron SARS-CoV-2 new variant: global prevalence and biological and clinical characteristics. Eur Rev Med Pharmacol Sci. 2021 Dec;25(24):8012-8018.
Kim MK, Lee B, Choi YY, et al. Clinical Characteristics of 40 Patients Infected With the SARS-CoV-2 Omicron Variant in Korea. J Korean Med Sci. 2022 Jan 17;37(3):e31.
Torjesen I. Covid-19: Omicron may be more transmissible than other variants and partly resistant to existing vaccines, scientists fear. BMJ. 2021 Nov 29;375:n2943.
(WHO) 2021. Update on Omicron. https://www.who.int/news/item/28-11-2021-update-on-omicron (Access Date: 29/01/2022).
Chan MCW, Hui KPY, Ho J, et al. SARS-CoV-2 Omicron variant replication in human respiratory tract ex vivo. ResearchSquare 2022; doi: 10.21203/rs.3.rs-1189219/v1.
Garcia-Beltran WF, St Denis KJ, Hoelzemer A, et al. mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant. medRxiv [Preprint]. 2021 Dec 14:2021.12.14.21267755. doi: 10.1101/2021.12.14.21267755.
Diamond M, Halfmann P, Maemura T, et al. The SARS-CoV-2 B.1.1.529 Omicron virus causes attenuated infection and disease in mice and hamsters. Res Sq [Preprint]. 2021 Dec 29:rs.3.rs-1211792. doi: 10.21203/rs.3.rs-1211792/v1.
McMahan K, Giffin V, Tostanoski LH, et al. Reduced Pathogenicity of the SARS-CoV-2 Omicron Variant in Hamsters. BioRxiv [Preprint] doi: https://doi.org/10.1101/2022.01.02.474743
Bentley EG, Kirby A, Sharma P, et al. SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19. BioRxiv [Preprint] doi: https://doi.org/10.1101/2021.12.26.474085
SARS-CoV-2 variants of concern and variants under investigation in England. Technical briefing 31. December 10, 2021.https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1040076/Technical_Briefing_31.pdf (Access Date: 29/01/2022).
Peacock RP, Brown JC, Zhou J, et al. The SARS-CoV-2 variant, Omicron, shows rapid replication in human primary nasal epithelial cultures and efficiently uses the endosomal route of entry. Unpublished. https://www.biorxiv.org/content/10.1101/2021.12.31.474653v1.full.pdf (Access Date: 30/01/2022).
Pulliam JRC, van Schalkwyk C, Govender N, et al. Increased risk of SARS-CoV-2 reinfection associated with emergence of the Omicron variant in South Africa 2021-12-01. Unpublished. https://www.medrxiv.org/content/10.1101/2021.11.11.21266068v2.full.pdf (Access Date: 29/01/2022).
Altarawneh H, Chemaitelly H, Tang P, et al. Protection afforded by prior infection against SARS-CoV-2 reinfection with the Omicron variant. Unpublished. https://www.medrxiv.org/content/10.1101/2022.01.05.22268782v1.full.pdf (Access Date: 29/01/2022).
Rössler A, Riepler L, Bante D, et al. SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons. N Engl J Med. 2022 Jan 12:NEJMc2119236. doi: 10.1056/NEJMc2119236.
Maslo C, Friedland R, Toubkin M, et al. Characteristics and Outcomes of Hospitalized Patients in South Africa During the COVID-19 Omicron Wave Compared With Previous Waves. JAMA. 2021 Dec 30:e2124868.
Wolter N, Jassat W, Walaza S, et al. Early assessment of the clinical severity of the SARS-CoV-2 omicron variant in South Africa: a data linkage study. Lancet. 2022 Jan 19;399(10323):437–46. doi: 10.1016/S0140-6736(22)00017-4. Epub ahead of print.
Abdullah F, Myers J, Basu D, et al. Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa. Int J Infect Dis. 2021 Dec 28;116:38-42. doi: 10.1016/j.ijid.2021.12.357.
(Omicron Severity Update) 2021. Technical Briefing. https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/1044481/Technical-Briefing-31-Dec-2021-Omicron_severity_update.pdf (Access Date: 30/01/2022).
Lewnard JA, Hong VX, Patel MM, et al. Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California. 2022 Jan 11. medRxiv preprint doi: https://doi.org/10.1101/2022.01.11.22269045
Zhang L, Mann M, Syed Z, et al. Furin cleavage of the sars-cov-2 spike is modulated by o-glycosylation. Proceedings of the National Academy of Science of the United States of America, 118(47):e2109905118, 2021.
Rui Wang, Jiahui Chen, Yuta Hozumi, et al. Emerging vaccinebreakthrough SARS-CoV-2 variants. arXiv preprint arXiv:2103.08023, 2021.
He X, Hong W, Pan X, et al. Omicron variant: Characteristics and prevention. MedComm (2020). 2021 Dec 16;2(4):838–45. doi: 10.1002/mco2.110. Epub ahead of print.
Karim SSA, Karim QA. Omicron SARS‐CoV‐2 variant: a new chapter in the COVID‐19 pandemic. Lancet. 2021;398(10317):2126‐2128.
Harvey WT, Carabelli AM, Jackson B, et al. SARS-CoV-2 variants, spike mutations and immune escape. Nat Rev Microbiol 2021; 19: 409–24.
Wilhelm A, Widera M, Grikscheit K, et al. Reduced Neutralization of SARS-CoV-2 Omicron Variant by Vaccine Sera and monoclonal antibodies. 2021; medRxiv preprint doi: https://doi.org/10.1101/2021.12.07.21267432
Hoffmann M, Krüger N, Schulz S, et al. The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic. Cell. 2021 Dec 24:S0092-8674(21)01495-1. doi: 10.1016/j.cell.2021.12.032.
Liu L, Iketani S, Guo Y, et al. Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-2. Nature. 2021 Dec 23. doi: 10.1038/s41586-021-04388-0. Epub ahead of print. PMID: 35016198.
Kuhlmann C, Mayer CK, Claassen M, Maponga T, Burgers WA, Keeton R, Riou C, Sutherland AD, Suliman T, Shaw ML, Preiser W. Breakthrough infections with SARS-CoV-2 omicron despite mRNA vaccine booster dose. Lancet. 2022 Jan 18:S0140-6736(22)00090-3. doi: 10.1016/S0140-6736(22)00090-3. Epub ahead of print.
